title: The Malaria Vaccine Epidemiology and Evaluation Project of Papua New Guinea: rationale and baseline studies.
abstract: The range of possible malaria vaccines, against different species of Plasmodium and various stages in the life cycle of the parasite in both human host and mosquito vector, is reviewed. The importance, in a malaria-endemic area, of protection by a malaria vaccine against disease rather than infection is emphasized, and the ways by which disease prevention may be achieved are discussed. Mechanisms of production and presentation of vaccines are considered, including the importance of appropriate and more effective adjuvants. The variety of immune responses to malaria is set out and linked to both human and plasmodial genetic factors. Host genetics may also modify susceptibility to malaria through mechanisms which are not immunological. There is a need for entomological studies of the Anopheles vectors, especially but not only in preparation for transmission-blocking vaccines. This overall complexity justifies a multidimensional approach to epidemiology and field-site preparation. An iterative procedure is proposed for initial field evaluation, through adult male volunteers to community studies in immune adults and then to semi-immune school children, before evaluation in the principal target population of nonimmune young children. The outcome variables for epidemiological evaluation are specified. After this brief review of malaria vaccines, the baseline studies being undertaken by the Malaria Vaccine Epidemiology and Evaluation Project of the Papua New Guinea Institute of Medical Research in the Wosera area of East Sepik Province are discussed in some detail, and their rationale linked to the range and complexity of the malaria vaccines that have been reviewed. These studies are described under the headings of their principal components of epidemiology, parasitology, immunology, genetics and entomology.
authors.affiliation: Papua New Guinea Institute of Medical Research, Goroka.
authors.forename: M P
authors.initials: MP
authors.lastname: Alpers
authors.forename: F
authors.initials: F
authors.lastname: al-Yaman
authors.forename: H P
authors.initials: HP
authors.lastname: Beck
authors.forename: K K
authors.initials: KK
authors.lastname: Bhatia
authors.forename: J
authors.initials: J
authors.lastname: Hii
authors.forename: D J
authors.initials: DJ
authors.lastname: Lewis
authors.forename: R
authors.initials: R
authors.lastname: Paru
authors.forename: T A
authors.initials: TA
authors.lastname: Smith
mesh_terms: D000818:Animals; D000852:Anopheles; D002986:Clinical Trials as Topic; D003140:Communicable Disease Control / Q000379:methods; D006680:HLA Antigens; D006650:Histocompatibility Testing; D006801:Humans; D008288:Malaria / Q000453:epidemiology / Q000469:parasitology / Q000517:prevention & control* / Q000635:transmission; D017780:Malaria Vaccines / Q000145:classification / Q000276:immunology / Q000494:pharmacology; D009032:Mosquito Control; D010219:Papua New Guinea / Q000453:epidemiology; D010961:Plasmodium / Q000235:genetics / Q000276:immunology*
chemical_list: D006680:HLA Antigens; D017780:Malaria Vaccines